Abiopharma

🔍 Hartley Lindsey Marie (Executive)

Company: Axogen, Inc. (AXGN)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 2,500 shares of Common Stock at $8.2 per share (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,234.00 | transaction_form_type: 4
• Sold 478 shares of Common Stock at $43.67 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,756.00 | transaction_form_type: 4
• Acquired 2,963 shares of Common Stock at $8.27 per share (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 65,719.00 | transaction_form_type: 4
• Sold 573 shares of Common Stock at $43.67 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,146.00 | transaction_form_type: 4
• Sold 2,500 shares of Employee Stock Option (right to purchase) at $8.2 per share (Derivative)
  Date: 2026-05-07 | Code: M | Expires: 2032-03-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,963 shares of Employee Stock Option (right to purchase) at $8.27 per share (Derivative)
  Date: 2026-05-07 | Code: M | Expires: 2033-03-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026.
• F2: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.